RheumaFinder Receives ISO 13485 Certification – A Key Step on the Path to the CE Mark of its product RFMaple
Ghent, Belgium — 07 October 2026 RheumaFinder, the Ghent-based UZ Gent spin-out developing AI-driven CT screening support for structural bone lesions…
We welcome Wim Van Hecke as new RheumaFinder board member
We are excited to announce that Wim Van Hecke, PhD, has joined the RheumaFinder board! Wim is a pioneer in…
Expert Opinion Paper published in Virchows Archiv European Journal of Pathology
Making the complex EU AI Act more accessible for pathology labs is crucial for safe and effective AI adoption in…
World Arthritis Day, October 12th
At RheumaFinder, we proudly join the global community to highlight the significance of rheumatic and musculoskeletal diseases (RMDs). These conditions…
RheumaFinder at ESSR 2025: Engaging with MSK Radiology Leaders
We are pleased to announce that RheumaFinder will be participating in this year’s European Society for Musculoskeletal Radiology (ESSR) Annual…
Unite for a Cause: World AutoImmune Arthritis Day and RheumaFinder’s Commitment
Today, May 20th, marks World AutoImmune Arthritis Day—a global initiative dedicated to raising awareness and shaping the conversation around autoimmune…
Understanding Axial Spondyloarthritis (AxSpA): Raising Awareness on World AxSpA Day
Introduction On May 3rd, we commemorate World Axial Spondyloarthritis (AxSpA) Day, an important occasion to raise awareness about this chronic…
CrossCare
Het project CrossCare 2.0 stimuleert, ondersteunt en versnelt innovaties in de zorg. RheumaFinder maakt gebruik van dit programma om de implementatie van AI-gestuurde…
Discover How AI is Transforming Healthcare: Insights from EOS Magazine
We are pleased to share insights from our co-founder, Prof. dr. Lennart Jans, recently featured in EOS magazine. The article…
RheumaFinder Gears Up for a Busy Spring Conference Season
We are excited to announce our upcoming conference engagements for the spring season, where RheumaFinder will be actively participating and…
RheumaFinder Hosts Successful Investor Event
At RheumaFinder, we are constantly seeking innovative solutions to improve the incidental detection of clinically relevant structural joint lesions, ultimately…
RheumaFinder Celebrates an Important Milestone: Thomas Van Den Berghe Completes PhD
RheumaFinder is thrilled to announce a significant achievement for our co-founder, Thomas Van Den Berghe, who successfully defended his PhD…